AI In Life science Analytics Market Size, Share & Trends Analysis Report By Delivery (Cloud, On-premise), By Component (Software, Hardware, Services), By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030

AI In Life science Analytics Market Trends

The global AI in life science analytics market size was estimated at USD 1.7 billion in 2023 and is projected to grow at a CAGR of 10.9% from 2024 to 2030. The global market is experiencing significant growth driven by advancements in AI and machine learning technologies. These innovations have enhanced the analysis of complex and large-scale datasets, thereby improving drug discovery, personalized medicine, and patient care.

In addition, increased investments from pharmaceutical companies and government initiatives supporting AI research and development are contributing to market expansion. AI's capabilities in streamlining clinical trials, optimizing supply chain management, and enhancing decision-making processes are further accelerating its adoption within the life sciences industry.

Life sciences industries focus on enhancing health through innovative medical solutions, including drug development, critical disease treatments, and minimally invasive surgical equipment to improve patient outcomes and recovery times. Companies are actively advancing AI innovation in this sector. For example, in October 2023, Fujitsu Limited and RIKEN's HPC- and AI-driven Drug Development Platform Division introduced an AI technology that predicts protein structural changes from electron microscope images, generating 3D density maps using generative AI.

Government initiatives supporting AI in life sciences vary globally, reflecting diverse strategies to leverage AI for healthcare, biomedical research, and pharmaceutical innovation. These initiatives aim to accelerate technological advancements, foster cross-sector collaboration, and address regulatory and ethical challenges. Notably, the U.S. has made substantial progress with the National Artificial Intelligence Initiative Office (NAIIO), established in early 2021, which coordinates AI research and development across federal agencies, academia, and industry.

The COVID-19 pandemic had a transformative effect on the health and life sciences industries. The disruption of supply chains and clinical development during the pandemic accelerated innovation, leading to a significant increase in AI adoption for life sciences analytics. This shift is driven by rising clinical trials, drug discoveries, and advancements in deep learning technologies, all contributing to market growth.

Key players in the market are increasingly focused on enhancing their AI-based tools to improve quality and capabilities. In March 2022, Sorcero launched 'Clarity,' a tool designed to offer medical affairs teams an integrated view across all areas of scientific engagement. Utilizing Sorcero’s advanced analytics, medical teams can now visualize and track medical content at scale. In addition, in 2022, CloudMedx introduced 'ACO REACH Explorer,' aimed at unifying and visualizing disparate data to enhance health equity and Omni channel patient engagement.

Case Study

A leading pharmaceutical company required precise monitoring of the market share of its consumer health and medication products. The company aimed to identify future business prospects for each product, assess their market contributions, and analyze key factors influencing market growth.

The Microsoft Excel-based classification model required substantial manual intervention, resulting in rework and human error. Therefore, the manufacturer sought a scalable, AI-based solution to automate market share analytics categorization.

Solution

Cognizant designed an AI-powered intelligence system using several advanced technologies

Result

This engagement enhanced operational efficiency, enabling the manufacturer to focus on more value-added, less repetitive tasks. It also significantly enhanced the customer experience by simplifying the categorization and sorting of sales for specific consumer health and medication products.

Market Concentration & Characteristics

The degree of innovation within the market is high, driven by continuous advancements in AI algorithms, machine learning techniques, and the integration of big data analytics. AI is revolutionizing how data from genomics, proteomics, clinical trials, and patient records are analyzed and utilized to drive insights and discoveries in life sciences. Innovations in natural language processing (NLP), computer vision, and predictive analytics are pushing the boundaries of what is possible in drug discovery, personalized medicine, and healthcare delivery.For instance, PathAI uses AI to analyze pathology images and aid pathologists in diagnosing diseases like cancer with higher accuracy. This technology not only enhances diagnostic capabilities but also improves patient outcomes by ensuring timely and precise diagnoses.

Mergers and acquisitions (M&A) activities in the global market are on the rise as companies strive to enhance their technological capabilities, expand market reach, and integrate complementary solutions. Larger pharmaceutical companies, healthcare providers, and technology firms are increasingly acquiring AI startups and specialized analytics firms to gain access to advanced AI algorithms, proprietary data sets, and expertise in applying AI to the life sciences sector.

For example, in March 2024, Clarivate Plc, a global intelligence solutions provider, announced its intention to acquire most assets from MotionHall, a Silicon Valley startup specializing in AI solutions for the life sciences sector. This acquisition aligns with Clarivate's strategy to strengthen its Life Sciences and healthcare offerings through the incorporation of generative AI and proprietary industry-specific AI solutions. Similarly, in 2021, Medidata Solutions, a subsidiary of Dassault Systèmes, acquired MC10, a company specializing in wearable biosensor technology and data analytics. This acquisition aimed to integrate MC10’s AI-driven analytics capabilities with Medidata’s clinical trial solutions, thereby enhancing real-time data insights and patient monitoring capabilities.

Regulations play a critical role in shaping the market, influencing data privacy standards, ethical considerations, and the approval process for AI-driven medical devices and pharmaceuticals. Regulatory bodies such as the FDA in the U.S and the EMA in Europe are actively developing guidelines and frameworks to ensure the safety, efficacy, and ethical use of AI technologies in healthcare. The FDA has established a regulatory pathway for AI-based medical devices through its Digital Health Innovation Action Plan. This framework provides clear guidelines for developers seeking approval for AI algorithms used in medical diagnostics, monitoring, and treatment planning. Similarly, the EU's AI Act provides a thorough regulatory framework for AI usage, offering life sciences companies clarity on safe and responsible AI practices. It outlines development and deployment requirements, prohibited AI use cases, and penalties for non-compliance.

Geographic expansion plays a key role in driving the market growth by fostering collaboration, access to diverse datasets, and talent pools across regions. It enables companies to tap into new markets, leverage local expertise, comply with region-specific regulations, and gain insights from different healthcare systems, ultimately fueling innovation and accelerating the adoption of AI technologies in life sciences globally.

Delivery Insights

Based on delivery, the cloud segment led the market with the largest revenue share of 51.1% in 2023. It is also expected to grow at the fastest CAGR over the forecast period, due to its scalability, flexibility, and cost efficiency. Cloud providers offer AI-specific services and tools that streamline the development, training, and deployment of machine learning models in life sciences. These platforms provide access to pre-built AI algorithms, model development frameworks, and automated workflows that simplify the AI lifecycle management process. For instance, Microsoft Azure offers cost-effective AI solutions for life sciences, including AI-powered analytics and machine learning tools. Azure's flexible pricing options and comprehensive cloud services support organizations in optimizing research budgets and achieving operational efficiencies through scalable AI deployments.

The on-premise segment is anticipated to grow at the substantial CAGR during the forecast period, as they support internal system integration, enable custom feature requests, and incorporate hardware capabilities. Users can fully control security measures and customize IT configurations to meet specific cybersecurity needs. These solutions also permit backup at personalized frequencies, allowing users to directly configure backup schedules and policies and design backup techniques and data strategies accordingly.

Component Insights

Based on component, the services segment led the market with the largest revenue share of 37.7% in 2023 and is also anticipated to grow at the fastest CAGR during the forecast period, due to the demand for AI implementation and integration services, complexity of AI solutions and technologies, and focus on customization and personalization. Organizations across sectors are increasingly recognizing the value of AI in enhancing operational efficiency, customer engagement, and decision-making processes. However, many lack the internal expertise to implement and integrate AI solutions effectively. This drives the demand for AI service providers who offer consulting, implementation, customization, and integration services. For instance, AI service providers like IBM Watson offer AI-as-a-Service platforms that enable businesses to access pre-built AI models and tools for various applications, such as predictive analytics and virtual assistants. These platforms simplify AI adoption by providing ready-to-use solutions and technical support.

Moreover, businesses increasingly seek AI solutions that are tailored to their specific needs and industry requirements. Service providers offer customization services that align AI capabilities with business objectives, workflows, and regulatory compliance. For instance, IQVIA’s AI software, used by life science and healthcare customers, uncovers critical insights into population well-being, including social determinants of health (SDoH), significantly influencing health outcomes. Hence, in June 2023, IQVIA won the “Best AI-based Solution for Healthcare” award at the sixth annual AI Breakthrough Awards. The recognition is for AI software, which includes natural language processing (NLP) technology to analyze complex, unstructured patient data and provide insights into patient care and disease states.

Application Insights

Based on application, the sales and marketing segment led the market with the largest revenue share of 33% in 2023. This growth is attributed to the increasing adoption of AI-driven solutions to enhance sales effectiveness, customer engagement, and market intelligence within the life sciences sector. AI enables life science companies to personalize customer interactions and engagement strategies based on individual preferences, behaviors, and historical data. Advanced analytics and AI algorithms analyze vast datasets, including customer profiles, purchasing patterns, and market trends, to segment audiences and deliver targeted marketing campaigns.

The research and development segment is expected to grow at a fastest CAGR over the forecast period. The rising adoption of analytical solutions in drug development and clinical trials is one of the driving factors for growth. Leading companies are constantly investing in the development of new innovative drugs for the treatment of many severe diseases such as cancer, diabetes, and other infectious diseases that necessitate extensive research and development. For instance, in December 2023, the U.S. Pharmacopeia (USP) inaugurated the USP Advanced Manufacturing Technology Lab in the U.S. as part of its new suite of R&D analytical solutions. These services aim to support drug manufacturers adopting advanced technologies, such as pharmaceutical continuous manufacturing (PCM), to improve diverse geographic presence in pharmaceutical production and strengthen supply chain resilience.

End-use Insights

Based on end use, the pharmaceutical segment led the market with the largest revenue share of 46.3% in 2023. AI enables pharmaceutical companies to embrace precision medicine approaches by analyzing patient data, genetic profiles, and biomarkers to tailor treatment strategies based on individual characteristics and disease complexities. For instance, Insilico Medicine uses AI to discover novel drug candidates and optimize molecular structures for pharmaceutical companies. By leveraging AI-driven drug discovery platforms, Insilico accelerates the identification of promising compounds, streamlines preclinical testing, and facilitates collaborative research partnerships to address unmet medical needs and improve patient outcomes. In addition, various government organizations are undertaking initiatives to promote the safe use of AI in the pharmaceutical field. For instance, in March 2024, the WHO developed a discussion paper to analyze the growing application of AI to each step of vaccine and medicine development and production.

The biotechnology segment is expected to grow at the fastest CAGR over the forecast period, owing to the advantages offered by the incorporation of AI technology such as, effective decision making, cost effectiveness, and accelerated R&D analysis of homogenous databases. Moreover, through integration of these tools the biotechnology firms can improve their workflows in order to gain competitive advantages and in development of therapies for various diseases. For instance, in November 2023, Evommune, Inc. and Accutar Biotechnology, Inc. announced a strategic alliance to identify new small-molecule therapeutic candidates to treat chronic inflammatory conditions. The collaboration utilizes Accutar's proprietary AI platform and Evommune's expertise in developing oral small-molecule treatments targeting the root causes of chronic immune-mediated inflammatory disorders.

Regional Insights

North America dominated the AI in life science analytics market with the revenue share of 50.23% in 2023. The increasing initiatives undertaken by the governments and collaborations among the government bodies and private players for development of technologically solutions is anticipated to drive the market growth. Furthermore, rapid adoption of the solutions by the healthcare institutions in order to organize the organizational workflows is anticipated to boost the market growth.

U.S. AI In Life Science Analytics Market Trends

The AI in life science market in the U.S. is driven by increased use of AI in various life science domains. For instance, in March 2023, NVIDIA announced expanded generative AI cloud services designed to customize AI foundation models, aiming to accelerate protein and therapeutic development and advance research in genomics, chemistry, biology, and molecular dynamics.

“The transformative power of generative AI holds enormous promise for the life science and pharmaceutical industries.”

- Vice President of healthcare at NVIDIA.

Europe AI In Life science Analytics Market Trends

The AI in life science analytics market in Europe is driven by rapid advancements in AI technology, significant investments, and supportive regulatory policies. The need to reduce healthcare costs, address a geriatric population, and manage chronic diseases further accelerates AI adoption. Collaborations between academia, research institutions, and industry enhance innovation, while improved data availability and a shift towards patient-centric healthcare models strengthen AI applications.

The UK AI in life science analytics market is significantly driven by government initiatives. For instance, in October 2023, the government announced a new USD 108.7 (EUR 100) million investment focused on rapidly deploying AI to achieve breakthroughs in therapies for incurable diseases. The AI Life Sciences Accelerator Mission is expected to use the UK’s strengths in securing advanced AI and health data.

The AI in life science analytics market in Germany is driven by strategic initiatives undertaken by the market players. For instance, in September 2023, Merck KGaA announced two strategic partnerships focused on leveraging advanced AI-driven drug development and discovery to enhance its research initiatives. Partnering with BenevolentAI in London and Exscientia in Oxford, these partnerships aim to develop novel drug candidates with best-in-class potential in oncology, neurology, and immunology.

Asia Pacific AI In Life Science Analytics Market Trends

The AI in life science analytics market in Asia Pacific is expected to grow at the fastest CAGR during forecast period. Rising number of countries aiming to adopt AI based tools and high presence of biotech companies are the reasons that are fueling the growth of market. Major players in Asia Pacific are more focusing on adoption of AI based analytical tools to enhance the operation efficiency also plays a crucial role in market growth.

The Japan AI in life science analytics market is driven by increased used of AI and ML technologies to develop healthcare solutions. For instance, in June 2023, Eisai, LifeArc, Health Data Research UK (HDR UK), Gates Ventures, and the University of Edinburgh announced a two-year research agreement named NEURii. This collaboration leverages collective expertise in therapeutics, health data management, commercialization, technology development, and advanced analytics/data science to focus on brain health. NEURii will utilize high-quality individual data, AI, and ML to develop patient-focused digital health solutions.

The AI in life science analytics market in India is expected to grow at a significant CAGR over the forecast period. The growth is driven by rapid technological advancements and expansion of healthcare facilities integrated with AI technologies. For instance, in March 2024, Axtria, a global cloud based software and data analytics for the life sciences sector, announced the opening of its 9^th innovation and Capability Centre in Hyderabad, India. This new facility expands Axtria's capacity to provide advanced AI-driven solutions and data analytics, including generative AI technologies, to support life sciences companies in achieving better health outcomes.

Key AI In Life Science Analytics Company Insights

The market is highly competitive, with numerous companies worldwide investing in AI-based tools to provide more effective analytical solutions. For example, in September 2021, IQVIA launched the AI-powered MI Contact Center for life sciences. This solution enables companies to share information through new virtual agents, complementing human experts to prioritize and respond to inquiries more efficiently.

Recent Developments

• In June 2024, Medidata launched Clinical Data Studio, a unified platform that integrates data from both Medidata and non-Medidata sources. This technology allows stakeholders to control data quality and deliver safer trials faster, accelerating decision-making and enabling holistic data and risk strategies. AI helps identify potential issues and safety signals.

• In April 2024, IQVIA and Salesforce announced broadening their global partnership to hasten the development of the Life Sciences Cloud. This collaboration integrates IQVIA OCE innovations with Salesforce's platform, offering customers a comprehensive engagement solution. Leveraging IQVIA's data, domain expertise, and advanced analytics, Salesforce's CRM software aims to revolutionize healthcare professional (HCP) and patient engagement, providing a seamless and effective experience.

• In January 2024, Cleveland Clinic and IBM researchers released a strategy using AI to identify new immunotherapy targets. This marks the initial peer-reviewed publication stemming from their Discovery Accelerator partnership, which aims to progress healthcare and life sciences research.

• In September 2023, SAS introduced SAS Health, a new AI and analytics solution catering to health insurers, providers, and public health agencies. This solution empowers them with flexibility and agility to drive health innovation, ultimately improving health outcomes and patient experiences.

• In August 2023, Indegene launched Invisage, an AI-enabled platform designed for life sciences companies to enhance their go-to-market strategies. Utilizing data from a vast network of healthcare professionals (HCPs) and interactions, InvisageTM facilitates personalized outcomes for HCPs, optimizing engagement and effectiveness in the industry.

• In March 2022, IQVIA introduced OCE+, the latest advancement in its prominent life science customer engagement platform. OCE+ integrates IQVIA’s Next Best recommendation engine into the Orchestrated Customer Engagement (OCE) platform, offering AI-driven suggestions for engaging healthcare professionals (HCPs). This addition enhances HCP experiences, boosts productivity, and increases user ROI.

AI In Life Science Analytics Market Report Scope

Global AI In Life Science Analytics Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global AI in life science analytics market report based on delivery, component, application, end-use, and region:

• Delivery Outlook (Revenue in USD Million, 2018 - 2030)

  • Cloud

  • On-premise

• Component Outlook (Revenue in USD Million, 2018 - 2030)

  • Software

  • Hardware

  • Services

• Application Outlook (Revenue in USD Million, 2018 - 2030)

  • Research and Development

  • Sales and Marketing Support

  • Supply Chain Analytics

  • Others

• End -use Outlook (Revenue in USD Million, 2018 - 2030)

  • Medical Devices

  • Pharmaceutical

  • Biotechnology

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain 

    • Sweden

    • Denmark

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Singapore

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait